Current State of Respiratory Syncytial Virus Disease and Management.
Current State of Respiratory Syncytial Virus Disease and Management.
复制标题
DOI：
10.1007/s40121-020-00387-2
复制
发表时间：
2021-03
影响因子：
5.4
通讯作者：
Krilov LR
中科院分区：
文献类型：
--
作者：
Chatterjee A;Mavunda K;Krilov LR
呼吸道合胞病毒(RSV)是肺炎和毛细支气管炎住院的主要原因。在世界范围内，RSV感染与相当大的发病率和社会经济负担有关。易患严重呼吸道合胞病毒的人群包括早产儿、患有慢性早产儿肺病或先天性心脏病的儿童、65岁的 >； 老年人和免疫功能低下的人。在儿科人群中，RSV可能会导致喘息和哮喘等长期后遗症，这些后遗症与医疗费用增加和生活质量下降有关。RSV的治疗主要是支持性的，强烈建议采取良好的卫生和隔离等一般预防措施。尽管RSV疫苗的开发一直是全球的优先事项，但迄今为止的尝试未能产生安全有效的临床使用产品。目前，Palivizumab是唯一可用于在特定高危儿童人群中预防严重RSV的免疫预防(IP)。经过良好控制的随机临床试验已经证实，帕利维珠单抗在包括中晚期早产儿在内的高危婴儿中减少呼吸道合胞病毒住院(RSVH)的有效性。然而，美国儿科学会在其2014年的政策中，停止推荐对29周的 ≥ 婴儿使用呼吸道合胞病毒IP。针对RSV IP的AAP政策的修订在很大程度上缩小了有资格接受RSV IP的儿科患者的比例，并与RSVH和发病率的增加有关。另一方面，在审查了最近关于RSV负担的证据后，国家围产期协会在其2018年临床实践指南中建议在更广泛的儿科人群中使用RSV IP。由于AAP的建议推动了RSV IP的保险报销，它们应该进行修订，以帮助进一步减轻RSV疾病负担。
Respiratory syncytial virus (RSV) is a major cause of hospitalizations due to pneumonia and bronchiolitis. Substantial morbidity and socioeconomic burden are associated with RSV infection worldwide. Populations with higher susceptibility to developing severe RSV include premature infants, children with chronic lung disease of prematurity (CLDP) or congenital heart disease (CHD), elderly individuals aged > 65 years, and immunocompromised individuals. In the pediatric population, RSV can lead to long-term sequelae such as wheezing and asthma, which are associated with increased health care costs and reduced quality of life. Treatment for RSV is mainly supportive, and general preventive measures such as good hygiene and isolation are highly recommended. Although vaccine development for RSV has been a global priority, attempts to date have failed to yield a safe and effective product for clinical use. Currently, palivizumab is the only immunoprophylaxis (IP) available to prevent severe RSV in specific high-risk pediatric populations. Well-controlled, randomized clinical trials have established the efficacy of palivizumab in reducing RSV hospitalization (RSVH) in high-risk infants including moderate- to late-preterm infants. However, the American Academy of Pediatrics (AAP), in its 2014 policy, stopped recommending RSV IP use for ≥ 29 weeks’ gestational age infants. Revisions to the AAP policy for RSV IP have largely narrowed the proportion of pediatric patients eligible to receive RSV IP and have been associated with an increase in RSVH and morbidity. On the other hand, after reviewing the recent evidence on RSV burden, the National Perinatal Association, in its 2018 clinical practice guidelines, recommended RSV IP use for a wider pediatric population. As the AAP recommendations drive insurance reimbursements for RSV IP, they should be revised to help further mitigate RSV disease burden.
登录
查看更多内容
影响因子：
3.7
作者：
Cebey-López M;Herberg J;Pardo-Seco J;Gómez-Carballa A;Martinón-Torres N;Salas A;Martinón-Sánchez JM;Gormley S;Sumner E;Fink C;Martinón-Torres F;GENDRES network
通讯作者：
GENDRES network
随机试验评估阿奇霉素对血清和上呼吸道IL-8水平的影响，并在患有呼吸道合胞病毒细支气管炎的婴儿中复发。
DOI：
10.1016/j.jaci.2014.10.001
发表时间：
2015-05
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Beigelman A;Isaacson-Schmid M;Sajol G;Baty J;Rodriguez OM;Leege E;Lyons K;Schweiger TL;Zheng J;Schechtman KB;Castro M;Bacharier LB
通讯作者：
Bacharier LB
DOI：
10.1056/nejmoa0804877
发表时间：
2009-02-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hall CB;Weinberg GA;Iwane MK;Blumkin AK;Edwards KM;Staat MA;Auinger P;Griffin MR;Poehling KA;Erdman D;Grijalva CG;Zhu Y;Szilagyi P
通讯作者：
Szilagyi P
影响因子：
3.6
作者：
Bont, L;Versteegh, J;Kimpen, JLL
通讯作者：
Kimpen, JLL
影响因子：
16.6
作者：
Gilman, Morgan S. A.;Furmanova-Hollenstein, Polina;McLellan, Jason S.
通讯作者：
McLellan, Jason S.